|
Cyplasin Biomedical Ltd. Announces Financing Edmonton, Alberta, January 11, 2008 CYPL: OTCBB, Frankfurt Exchange WKN:XYIA Cyplasin Biomedical is pleased to announce it has now completed an equity financing totalling US$1.1 million at US$1.00 per share. The use of proceeds from this investment will be for the Company’s R&D preclinical studies as well as finalizing the manufacturing of the Cyplasin-SC protein. Garth Likes, President and CEO of Cyplasin Biomedical, stated, "We wish to thank our investors for their continued support of the Company as we meet our product development goals. Using these funds will see us complete our scale-up manufacturing of Cyplasin-SC™ and initiate our toxicology programs which will allow us to file an Investigational New Drug (IND) application with the FDA in due course." Cyplasin-SC™ is being developed for use as an anticancer therapeutic drug for melanoma and skin cancer. About Cyplasin-SC™ Cyplasin-SC™ has demonstrated a selective ability to rapidly kill certain types of cancer cells while leaving normal non-cancerous cells untouched. Cyplasin-SC is a protein originally discovered and isolated by Professor Petzelt from a marine organism, the sea hare (Aplysia punctata). The protein can now be manufactured as a recombinant protein which allows the company to develop the protein as an anti-cancer therapeutic product. Patents have been issued to the Company covering the Cyplasin-SC protein. About Cyplasin Biomedical Ltd. (CBL) Founded in 2007 and headquartered in Edmonton, Canada with a research laboratory close to Berlin, Germany, CBL is dedicated to bringing new anticancer therapeutics to the marketplace. The Company’s current goal is to develop and commercialize the anticancer properties of Cyplasin-SC™ against skin cancer and melanoma. CBL is publicly traded (CYPL: OTCBB) Forward-Looking Statements This Press release includes and is based, inter alia, on forward-looking information and statements that are subject to risks and uncertainties that could cause actual results to differ. Such forward-looking information and statements are based without limitation, as statements regarding future drug development activities, anticipated products, or anticipated future revenues, benefits or advantages, and the future plans and objectives of the Company, that involve inherent risks and uncertainties and are subject to factors, many of which are beyond the Company's control, such as market acceptance of new products and services, changes in governmental regulations, interest rates, fluctuations in currency exchange rates and such other factors as may be discussed from time to time that may cause actual results or performance to differ materially from those currently anticipated in such statements. These expectations, estimates and projections are generally identifiable by statements containing words such as "expects", "believes", "estimates" or similar expressions. Although Cyplasin Biomedical Ltd., believes that its expectations and the information in this Press release were based upon reasonable assumptions at the time when they were made, it can give no assurance that those expectations will be achieved or that the actual results will be as set out in this Press release. Cyplasin Biomedical Ltd., makes no representation or warranty, expressed or implied, as to the accuracy, reliability or completeness of the information in the Press release, and neither Cyplasin Biomedical nor any of their directors, officers or employees will have any liability to you or any other persons resulting from your use of the information in the Press release. The OTCBB Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release. Contact:
|